Nisantasi Pathology Group, Istanbul.
Department of Pathology, University of Health Sciences, Bozyaka Training and Research Hospital.
Am J Surg Pathol. 2021 Sep 1;45(9):1252-1263. doi: 10.1097/PAS.0000000000001714.
Hepatocellular carcinomas (HCCs) with steatohepatitis and steatosis are reported with varying definitions and clinicopathologic features. We aimed to search the attributes of steatohepatitic hepatocellular carcinoma (SH-HCC) and steatotic-HCC in our series. A retrospective clinicopathologic analyses of 150 HCCs and immunostaining for C-reactive protein (CRP) and serum amyloid A (SAA) were performed. Tumors were reclassified as all SH-HCC, limited SH-HCC, typical SH-HCC (steatohepatitic features in >5%, 5% to 50%, and ≥50% of the tumor, respectively), steatotic-HCC, and classic HCC (C-HCC). Group comparisons were made using Kruskal-Wallis and Kaplan-Meier tests. The background etiology in all SH-HCCs was pure viral in 51.4%, nonalcoholic steatohepatitis (NASH)/alcoholic liver disease (ALD) alone/mixed in 34.3%, and unidentified in normal liver in 14.3%. All SH-HCCS (n=35, 23.3%) and typical SH-HCCs (n=13, 8.6%) had higher NASH/ALD. Limited SH-HCCs (n=22, 14.6%) had higher ALD (all P<0.05). Typical SH-HCCs tended to have more NASH (P=0.054). Steatotic-HCCs (n=13, 9%) and C-HCCs (n=102, 68%) had higher pure viral etiology and serum CRP (all P<0.05). CRP and SAA were positive in 69% and 27% of the tumors, respectively. SAA positivity correlated with ALD (P=0.026). In the overall group disease-free survival rates at 1, 5, 10, and 20 years were 97.0%, 82.3%, 79.6%, and 77.2%, respectively. Demographics, tumor characteristics, CRP and SAA positivity, and survival were similar between the groups (P>0.05). SH-HCC is heterogenous in terms of underlying etiologies, and can be seen in NASH/ALD, pure viral and noncirrhotic/normal background. The ≥50% cutoff for the definition of SH-HCC can lead to overlook ALD-related SH-HCC. Steatotic-HCC seems more similar to C-HCC rather than SH-HCC, but none of them feature as a different prognostic group.
具有脂肪性肝炎和脂肪变性的肝细胞癌(HCCs)的报道具有不同的定义和临床病理特征。我们旨在探讨我们系列中脂肪性肝炎性肝细胞癌(SH-HCC)和脂肪变性-HCC 的特征。对 150 例 HCC 进行回顾性临床病理分析,并进行 C 反应蛋白(CRP)和血清淀粉样蛋白 A(SAA)的免疫染色。肿瘤被重新分类为所有 SH-HCC、有限 SH-HCC、典型 SH-HCC(分别为肿瘤中>5%、5%至 50%和≥50%的脂肪性肝炎特征)、脂肪变性-HCC 和经典 HCC(C-HCC)。使用 Kruskal-Wallis 和 Kaplan-Meier 检验进行组间比较。所有 SH-HCCs 的背景病因在纯病毒性者中占 51.4%,非酒精性脂肪性肝炎(NASH)/酒精性肝病(ALD)单独/混合者占 34.3%,不明原因正常肝脏者占 14.3%。所有 SH-HCCS(n=35,23.3%)和典型 SH-HCC(n=13,8.6%)的 NASH/ALD 更高。有限 SH-HCC(n=22,14.6%)的 ALD 更高(均 P<0.05)。典型 SH-HCC 更倾向于有更多的 NASH(P=0.054)。脂肪变性-HCC(n=13,9%)和 C-HCC(n=102,68%)的纯病毒性病因和血清 CRP 更高(均 P<0.05)。肿瘤的 CRP 和 SAA 阳性率分别为 69%和 27%。SAA 阳性与 ALD 相关(P=0.026)。在总人群中,1、5、10 和 20 年无病生存率分别为 97.0%、82.3%、79.6%和 77.2%。各组间的人口统计学、肿瘤特征、CRP 和 SAA 阳性率和生存情况相似(P>0.05)。SH-HCC 的基础病因具有异质性,可在 NASH/ALD、纯病毒性和非肝硬化/正常背景中见到。SH-HCC 定义中≥50%的界限可能导致忽视与 ALD 相关的 SH-HCC。脂肪变性-HCC 似乎与 C-HCC 更为相似,而不是与 SH-HCC,但其均无不同的预后组特征。